Jay Rothstein, Ph.D., has more than 30 years of experience as a translational immunobiologist leading discovery, PK/PD, toxicological assessment, and proof-of-concept models for immune-modulatory drugs.

Most recently, he was Chief Scientific Officer at ImmuNext where he was instrumental in helping to establish five strategic research partnerships with leading pharmaceutical and biotech companies, including Eli Lilly, Sanofi, Roche, Janssen (Johnson & Johnson), and Curis. Previously, Dr. Rothstein was Director of Inflammation Research at Amgen where he championed a novel class of immunomodulatory drugs for the treatment of autoimmune disease. During his nine years at Amgen, he helped in cross-functional teams to evaluate and develop Amgen’s early immune-oncology drug pipeline, which included novel bispecifics such as BiTEs, as well as novel drugs to target immunometabolism. Before Amgen, Dr. Rothstein was a Professor of Otolaryngology-HNS at the Kimmel Cancer Institute of Thomas Jefferson University for 13 years, where his laboratory was responsible for discovering an association between oncogenes and chronic inflammation leading to a better understanding of the tumor microenvironment.

Dr. Rothstein holds a Ph.D. in Tumor Immunology from the University of Chicago and a B.S. in Microbiology/Molecular Biology from Pennsylvania State University.